Targeted delivery system of multivalent conjugate based on polydopamine nanosphere coupling aptamer as well as drug loading method and application of targeted delivery system

Through a multivalent conjugate targeted delivery system based on polydopamine nanosphere coupled aptamers, the problem of insufficient targeting of chemotherapy drugs and major side effects in breast cancer treatment is solved, and high efficiency is achieved on triple-negative breast cancer cells Targeted delivery reduces the toxic side effects of the drug and enhances the therapeutic effect.

CN118949067APending Publication Date: 2024-11-15HENAN UNIVERSITY
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202411014896.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Chemotherapeutic drugs such as hydroxy-paclitaxel and doxorubicin in the treatment of existing breast cancer have problems such as insufficient targeting, large side effects, and difficulty in targeting tumor cells. Especially in the treatment of triple-negative breast cancer, traditional nanodelivery systems are facing targets. Challenges such as insufficient tropism, high immunogenicity, and uncontrollable biodistribution.

Method used

Using a multivalent conjugate targeted delivery system based on polydopamine nanosphere coupled aptamers, chemotherapy drugs are loaded through mesoporous polydopamine nanospheres and bound to targeted nucleic acid aptamers to form polydopamine as the core. , nucleic acid aptamer is a spherical nanomaterial with a shell, and uses the targeted nature of nucleic acid aptamer to identify overexpressed nucleolin receptors on the surface of tumor cell membranes to achieve specific targeted delivery of triple-negative breast cancer cells.

Benefits of technology

It improves the efficiency of drug enrichment in tumor sites, reduces the toxic side effects of drug on organisms, enhances the anti-tumor treatment effect, and is simple and easy to operate, has good material stability, and is suitable for biomedical research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949067A_ABST
    Figure CN118949067A_ABST
Patent Text Reader

Abstract

The invention provides a targeted delivery system based on a polydopamine nanosphere coupled aptamer and a drug loading method and application thereof, and the targeted delivery system comprises mesoporous polydopamine nanospheres and chemotherapeutic drugs loaded in the mesoporous dopamine nanospheres, the surfaces of the mesoporous polydopamine nanospheres are modified with targeted nucleic acid chain aptamers; a nucleic acid chain modified on the outer layer of the prepared nano drug delivery system is an aptamer with targeting property, and due to the characteristics of high affinity, high specificity, low immunogenicity and the like, the aptamer can specifically recognize a nucleolin receptor over-expressed on the surface of a tumor cell membrane, and accurate targeting of triple negative breast cancer cells difficult to target is achieved. The medicine is high in cellular uptake efficiency, can be quickly gathered to a tumor site, enhances the enrichment of the medicine at the tumor site, reduces the toxic and side effects of chemotherapeutic medicines on organisms, and enhances the anti-tumor treatment effect. The preparation process is simple, the cost is low, the biocompatibility is good, the cell uptake efficiency is high, and a good foundation is established for a targeted delivery system.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical materials, and in particular to a multivalent conjugate targeted delivery system based on polydopamine nanosphere-coupled aptamers, and a preparation and drug-carrying method and application thereof. Background Art

[0002] Breast cancer is the second most common type of cancer in the world, second only to lung cancer. Although most breast cancers have a good prognosis, about 15% are triple-negative breast cancer (TNBC), which is prone to spread, metastasis and recurrence, and has limited treatment options. It is considered a more aggressive breast cancer due to the lack of therapeutic targets.

[0003] Hydroxy-paclitaxel (6α-hydroxypaclitaxel) is a major metabolite of paclitaxel. The molecular formula of paclitaxel is C 47 H 51 NO 14 Paclitaxel itself is a well-known diterpene alkaloid compound, which has attracted widespread attention due to its unique chemical structure and definite anticancer activity. It is a white crystalline powder, insoluble in water, but soluble in a variety of organic solvents. Generally, the oral bioavailability of insoluble drugs is low. In addition, it may bring some problems and challenges in the treatment of breast cancer: Hydroxy-paclitaxel may cause peripheral neuropathy, manifested as sensory, motor and autonomic nerve defects, and common symptoms include numbness, tingling and paresthesia; paclitaxel drugs may cause bone marrow suppression, which is a dose-limiting toxicity, manifested as a decrease in leukocytes and neutrophils; problems such as muscle and joint pain may occur after treatment. Improving the targeting of drugs and reducing systemic toxicity are technical issues that need to be solved urgently.

[0004] Doxorubicin is a widely used chemotherapeutic drug that induces cell death through multiple intracellular targets, including reactive oxygen species generation, DNA adduct formation, topoisomerase II inhibition, histone evoked protein, Ca 2+ Due to the regulation of hemostasis and iron and the overproduction of ceramide, doxorubicin can be used to treat a variety of cancer types, including acute leukemia, malignant lymphoma, breast cancer, ovarian cancer, lung cancer, soft tissue sarcoma, bladder cancer, thyroid tumor, prostate cancer, testicular cancer, gastric cancer, liver cancer, etc. However, the efficiency of doxorubicin is limited by side effects, such as cardiotoxicity and bone marrow suppression.

[0005] Nano-delivery systems have shown great potential in the treatment of TNBC, but face multiple challenges in practical applications, including insufficient targeting, high immunogenicity leading to rapid clearance, uncontrollable biodistribution and clearance pathways, etc. These problems need to be solved through continuous research and innovation.

[0006] Low toxicity and high efficiency of drugs have always been difficult points in research. Chemotherapy is the main means of treating cancer clinically, but traditional chemotherapy drugs currently lack targeting. While killing tumor cells, they are also toxic to normal cells, causing toxic side effects that patients cannot tolerate. Therefore, constructing drug carriers that can target tumor tissues is an effective way to solve the problem of tumor chemotherapy.

[0007] Polydopamine (PDA) is the main component of the natural biological pigment - melanin. The particle has good stability, biodegradability, biocompatibility and photothermal conversion properties, and is an ideal carrier material. However, as a solid spherical nanoparticle, PDA has low drug loading and encapsulation efficiency for hydrophobic drugs. Summary of the invention

[0008] In view of the technical problems existing in the prior art, the present invention proposes a targeted delivery system based on a multivalent conjugate of polydopamine nanospheres coupled to aptamers, a drug loading method and application thereof. The nano-diagnostic and therapeutic agent has specific targeting to triple-negative breast cancer cells (4T1 and MCF-7), reduces the toxic and side effects of drugs on organisms, and enhances the anti-tumor therapeutic effect.

[0009] In order to achieve the above object, the technical solution of the present invention is achieved as follows: A multivalent conjugate targeted delivery system based on polydopamine nanospheres coupled with aptamers, wherein the targeted delivery system comprises mesoporous polydopamine nanospheres and targeted nucleic acid aptamers modified on their surfaces; The nucleotide sequence of the above-mentioned targeted nucleic acid aptamer is selected from any one of the nucleotide sequences shown in SEQ ID No. 1 to SEQ ID No. 6, and the 5' end thereof is modified with an NH2-C6- group.

[0010] The nucleotide sequence of the above-mentioned targeted nucleic acid aptamer is shown in SEQ ID No. 5 or SEQ ID No. 6, and the 5' end thereof is modified with an NH2-C6- group.

[0011] Preferably, the nucleotide sequence of the above-mentioned targeted nucleic acid aptamer is as shown in SEQ ID No. 5, and the 5' end thereof is modified with an NH2-C6- group.

[0012] The mass ratio of the targeted nucleic acid aptamer to the mesoporous polydopamine nanospheres is 0.8-1.2:1; the particle size of the targeted delivery system is 120-180nm; and the drug loading amount of the chemotherapy drug in the mesoporous polydopamine nanospheres is 30-40%.

[0013] The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system comprises the following steps: (1) Analytically pure F127 molecules (poloxamer F127) and 3, 3', 5, 5'-tetramethylbenzidine (TMB) were ultrasonically dissolved and dispersed in an alcohol aqueous solution for 4-8 hours, and a dopamine monomer (DA) Tris buffer was added and stirred for reaction. After the reaction, the precipitate was washed by centrifugation to obtain mesoporous polydopamine nanospheres; (2) dispersing and dissolving mesoporous polydopamine nanospheres, chemotherapy drugs hydroxy-paclitaxel and doxorubicin in a buffer solution, and obtaining dual-drug loaded polydopamine nanospheres after the reaction is completed; (3) The dual-drug loaded polydopamine nanospheres and nucleic acid aptamers are dispersed and dissolved in a buffer solution, reacted in an inert atmosphere, and centrifuged and washed to remove impurities after the reaction to obtain a multivalent conjugate targeted delivery system.

[0014] In the above step (1), the mass ratio of F127 molecule, 3, 3', 5, 5'-tetramethylbenzidine and dopamine monomer is 80-300:0.2-0.5:2-12; the stirring reaction condition is stirring the reaction at room temperature for 16-28 hours.

[0015] The alcohol-water solution is ethanol and water in a volume ratio of 3-6:4-10; the concentration of F127 molecules in the alcohol-water solution is 1-9 mg / mL; the pH of the Tris buffer solution is 8, and the mass volume ratio of dopamine monomer to Tris buffer solution is 2-12 mg:1-8 mL; the washing method is to wash the precipitate with ethanol, acetone and water 2-5 times.

[0016] In the above step (2), the mass ratio of the mesoporous polydopamine nanospheres to the chemotherapeutic drug is 1.5-2:1; the type of the chemotherapeutic drug is one or more; The above-mentioned chemotherapy drugs are hydroxy-paclitaxel and doxorubicin, and the mass ratio of hydroxy-paclitaxel to doxorubicin is 1:1.

[0017] The pH of the Tris buffer is 8-9, and the reaction conditions are to react at room temperature in the dark for 20-28 hours; after the reaction, the solid particles are washed by centrifugation to remove impurities by washing them alternately with methanol and water for 2-4 times.

[0018] In step (3), the equivalent ratio of the drug-loaded polydopamine nanospheres to the targeted nucleic acid aptamer is 1:2; and the inert gas is nitrogen, helium or argon.

[0019] The reaction conditions in step (3) are stirring at room temperature for 20-28 hours; the centrifugal washing method is washing with water 3-5 times.

[0020] A cancer drug prepared by the above method.

[0021] The aptamer of the present invention can specifically recognize the nucleolin receptor overexpressed on the surface of tumor cell membrane, and the above-mentioned multivalent conjugate targeted delivery system based on polydopamine nanosphere-coupled aptamer is used in the preparation of cancer treatment products.

[0022] The above-mentioned cancer drugs can effectively identify triple-negative breast cancer cells 4T1 and MCF-7 when treating breast cancer.

[0023] The present invention has the following beneficial effects: 1. The present invention establishes a targeted delivery system based on polydopamine nanospheres coupled with aptamers. The delivery system prepares polydopamine nanospheres by a one-pot method, then loads chemotherapy drugs, and finally connects "dense" aptamers on the surface of the nanospheres to form a spherical nucleic acid nanomaterial with polydopamine as the core and aptamers as the shell; the synthesis method used is simple and easy to operate, and is easy to mass produce.

[0024] 2. The material obtained by the method of the present invention has good stability and biosafety, and is suitable for the fields of nano-targeted delivery, biomedical research, etc.; the obtained nanoparticles are uniform in size and relatively small (about 150 nm), which is conducive to the transportation and absorption of drugs in the body.

[0025] 3. The shell of the high-density nucleic acid aptamer T20-SNA of the present invention can target tumor cells, reduce nuclease degradation, and improve the efficiency of cancer cell uptake. Therefore, the efficient targeted delivery system with polydopamine nanospheres as the core and aptamers as the shell can improve drug enrichment at the tumor site, reduce the toxic side effects of drugs on organisms, and enhance the anti-tumor treatment effect.

[0026] 4. The nucleic acid chain modified on the outer layer of the nanomaterial obtained by the method of the present invention is a targeted aptamer T20-SNA, which can specifically recognize the nucleolin receptor overexpressed on the surface of the tumor cell membrane, and accurately target the triple-negative breast cancer cells that are difficult to target; it has high cell uptake efficiency and can quickly gather at the tumor site, thereby enhancing the enrichment of drugs at the tumor site, reducing the toxic side effects of chemotherapy drugs on the organism, and enhancing the anti-tumor treatment effect.

[0027] 4. The purpose of the present invention is to overcome the shortcomings of the existing drug-carrying materials, such as the complex preparation process, high cost, and poor biocompatibility, by improving the cellular uptake efficiency of nanomaterials, enhancing the enrichment of drugs at the tumor site, and reducing the toxic and side effects of chemotherapeutic drugs. The high-density aptamer shell can target tumor cells, reduce nuclease degradation, and improve the uptake efficiency of cancer cells. Therefore, the efficient targeted delivery system with polydopamine nanospheres as the core and aptamers as the shell can improve the enrichment of drugs at the tumor site, reduce the toxic and side effects of drugs on organisms, and enhance the anti-tumor therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0029] Figure 1 TEM images of spherical nucleic acids prepared for DNA with six different spacer lengths.

[0030] Figure 2 Flow chart of the enzymatic digestion experiment.

[0031] Figure 3 The figure shows the enzyme resistance of six spherical nucleic acids (SNAs) of different lengths.

[0032] Figure 4 SEM and elemental analysis of T20-SNA (the scale bar in the figure is 500 nm).

[0033] Figure 5 Comparison of the uptake efficiency of drug-loaded mesoporous polydopamine nanospheres modified with six spherical nucleic acids (SNA) made with nucleic acid chains of different lengths.

[0034] Figure 6 These are SEM and TEM characterization images of PDA (mesoporous polydopamine nanospheres), PDA@PD (mesoporous polydopamine nanospheres loaded with drugs) and PDA-SNA (mesoporous polydopamine nanospheres loaded with drugs modified with high-density nucleic acids on the surface) of the present invention, and the scale bars are all 100 nm.

[0035] Figure 7 These are electron microscope images of the drug-loaded particles prepared in Example 3 and Comparative Documents 1 and 2; wherein a is a TEM image of the drug-loaded T20-SNA material prepared in Example 3; b is a TEM image of the drug-loaded PEG-PDA; and c is a TEM image of the drug-loaded RSNA.

[0036] Figure 8 Uptake diagram of rhodamine-loaded PDA (Rho-PDA) and Cy3 fluorescently modified PDA-SNA particles in 4T1 cells.

[0037] Fig. 9 This is a graph showing the uptake experiment of Rho-PDA particles and Cy3 fluorescence-modified PDA-SNA particles by MCF-7 cells.

[0038] Fig.10 This is a graph showing the uptake experiment of Rho-PDA particles and Cy3 fluorescence-modified PDA-SNA particles in normal human liver cells HL7702.

[0039] Fig.11 Flow cytometric analysis of the cellular uptake of Cy3-T20-DNA, Cy3-PDA-SNA and Rho-PDA in two triple-negative breast cancer cells; a is 4T1 cells and b is MCF-7 cells.

[0040] Fig.12 MTT experiment of dual-drug loaded PDA, PEG-PDA and PDA-SNA nanoparticles in two types of triple-negative breast cancer cells (TNBC).

[0041] Fig.13 This is the apoptosis experiment of dual bare drugs, PDA@PD, dual-drug loaded PDA-PEG, dual-drug loaded PDA-RSNA and dual-drug loaded PDA-SNA in 4T1 and MCF-7 triple-negative breast cancer cells; a is 4T1 cells and b is MCF-7 cells. . DETAILED DESCRIPTION

[0042] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] The nucleic acid sequences involved in this embodiment are shown in the following table: Among them, the sequence with Cy3 dye at the 3' end was used for cell uptake experiment, and the sequence without Cy3 was used for MTT experiment, TEM characterization, anti-enzyme cleavage experiment and cell apoptosis experiment.

[0044] Example 1: Sequence Optimization Experiment A method for loading chemotherapeutic drugs in a targeted drug delivery system based on a multivalent conjugate of polydopamine nanospheres coupled to aptamers, comprising the following steps: 1. Preparation of hollow mesoporous polydopamine nanospheres The reaction mechanism of dopamine oxidative self-polymerization is as follows: ; In the formula, n is a natural number greater than 2.

[0045] At room temperature, add 20 mL of deionized water and 30 mL of anhydrous ethanol to a conical flask with a rod-shaped magnet and keep stirring at medium speed. Weigh 80 mg of analytically pure Pluronic F127 molecules and add them to the above conical flask, stir to fully dissolve. Add 200 μg of 3, 3', 5, 5'-tetramethylbenzidine (TMB) powder to it, fully ultrasonicate, and maintain medium-speed stirring at room temperature for 6 hours. Weigh 2 mg of dopamine (DA) monomer powder and dissolve it in 5 mL of Tris buffer (pH 8), then add the mixed solution to the above reaction system and stir at room temperature for 24 hours. Centrifuge, retain the precipitate below, wash the precipitate alternately with ethanol and acetone 3 times, wash it with water 2 times, collect the centrifugal precipitate sample into a centrifuge tube, prepare it into a concentration of 0.1-5 mg / mL solution, and store it in a refrigerator at 4°C.

[0046] 2. Chemotherapy drug loading The PDA solution was centrifuged and the preservation solution was discarded. 1 mL of Tris (pH 8) buffer was added, and then mixed with Tris (pH 8) solution of hydroxy-paclitaxel (PTX-OH), and stirred at medium speed for 10 minutes at room temperature. Subsequently, Tris (pH 8) solution of doxorubicin (DOX) was added, and the mass volume ratio of mesoporous polydopamine nanospheres, chemotherapy drugs and buffer solution was 1.5 mg: 1 mg: 3 mL; PDA was reacted at room temperature in the dark for 24 hours, centrifuged, and the solid particles were washed alternately with methanol and water twice to obtain polydopamine nanospheres (PDA@PD) loaded with dual drugs (PTX and DOX). The prepared PDA@PD was stored in a 5% ethanol aqueous solution and stored in a refrigerator at 4°C.

[0047] 3. Construction of a spherical nucleic acid structure with PDA as the core (outer dense nucleic acid layer) PDA@PD and 2 equivalents of aptamer nucleic acid single strands (sequences shown in SEQ ID No.1-SEQ ID No.12) were added to a Tris buffer solution with a pH of 9, respectively. Under N2 protection, the mixture was stirred at room temperature for 24 hours, washed with water three times, and the precipitate was collected to obtain the dual-drug loaded spherical nucleic acid (PDA-SNA).

[0048] A total of 12 dual-drug loaded spherical nucleic acids with 6 different nucleic acid chain lengths (PDA-T3-SNA, PDA-T5-SNA, PDA-T10-SNA, PDA-T15-SNA, PDA-T20-SNA and PDA-T30-SNA) were prepared. The materials were placed on ultrafine copper meshes and their surface morphologies were observed using transmission electron microscopy, as shown in Figure 2. Figure 1 As shown: It can be seen that the sizes of several materials are relatively uniform, the morphology is a complete sphere, and the diameter is approximately in the range of 120-200 nm.

[0049] 4. Enzyme digestion experiment Enzyme digestion experimental steps Figure 2 As shown, the relevant nucleic acid materials (T3-SNA, T5-SNA, PDA-T10-SNA, T15-SNA, T20-SNA, T30-SNA12) were properly treated with nuclease DNase I, and HPLC curve analysis was performed at a constant temperature at various reaction times. The ratio of the peak area of ​​the original nucleic acid material to the internal standard on the HPLC curve was calculated, and this ratio reflects the strength of the nucleic acid material's resistance to enzyme cleavage: ; Intact DNA fragment = enzyme resistance rate / 100; Where S is the peak area corresponding to intact DNA on HPLC, S(sample) is the peak area corresponding to the material, and S(standard) is the peak area corresponding to the original DNA that has not been treated with DNase I.

[0050] The results are as follows Figure 3 As shown in the figure, the resistance of nucleic acid materials to enzymatic cleavage increases with the number of T bases in the nucleic acid spacer. When the number of T bases increases to 20, the anti-enzymatic effect (~80%) is higher than the anti-enzymatic ratio of conventional polydisperse SNA (40-50%). This not only shows that for nucleic acid complex materials, the spherical three-dimensional structure helps to increase its nuclease resistance, but also for the length of the nucleic acid sequence, the longer the nucleic acid chain, the stronger the ability to resist enzyme degradation. This may be because longer nucleic acid chains have greater steric hindrance, making the overall material less susceptible to nuclease attack. Therefore, the sequence of T20-SNA was selected for further analysis.

[0051] 5. Element analysis test In the elemental analysis test, only T20-SNA and T30-SNA have relatively rich P content, while the P element signals of the other four SNAs with low T base content are extremely weak (the P element of T3-SNA and T-5-SNA materials was not detected, and the P element content of T10-SNA and T15-SNA was less than 1.5%). Figure 4The weight percentage of P element in T20-SNA (shown) and T30-SNA (2.01%) is higher than 2%. We believe that the reason is that the aptamer is different from the ordinary nucleic acid single strand, and the specific sequence makes the aptamer have a complex three-dimensional structure (such as quadruplex, hairpin structure, etc.). The shorter the T base sequence in the spacer region, the more severely the terminal amino group of the nucleic acid single strand is wrapped, the greater the steric hindrance, and the more difficult it is to modify it on the PDA nanosphere. On the contrary, the nucleic acid sequence with more T base content greatly reduces the steric hindrance of the active group (terminal amino group) of the nucleic acid chain, and significantly improves the reactivity and activity, making the nucleic acid layer on the surface of the prepared SNA more dense and closer to the SNA structure, thereby showing better SNA properties (such as resistance to enzyme degradation, efficient cell uptake without the assistance of transfection agents, etc.). Therefore, T20-SNA was selected for further research.

[0052] 6. Cell uptake efficiency experiment SK-OV-3 cells were incubated with culture medium containing Cy3-SNA (PDA 40 μg) prepared with six nucleic acid lengths at constant temperature for 1-6 hours, and then the nuclei were stained with Hoechest dye for 10 minutes, washed three times with PBS, and the cell uptake of the samples was observed using a laser confocal microscope as follows.

[0053] From the confocal images ( Figure 5 ) It can be seen that with the increase of T base content, the cell uptake efficiency of the final material gradually increases, among which T20-SNA and T30-SNA have better cell uptake efficiency. Taking into account factors such as cost (the more base content, the more difficult it is to prepare and purify the nucleic acid chain, and the higher the price) and effect, NH2-T20-AS1411 (T20-DNA) oligonucleotide chain was finally selected as the best choice for subsequent experiments.

[0054] Example 2 A method for loading chemotherapeutic drugs in a targeted drug delivery system based on a multivalent conjugate of polydopamine nanospheres coupled to aptamers, comprising the following steps: 1. Preparation of hollow mesoporous polydopamine nanospheres The reaction mechanism of dopamine oxidative self-polymerization is as follows: ; In the formula, n is a natural number greater than 2.

[0055] At room temperature, add 50 mL of deionized water and 15 mL of anhydrous ethanol to the conical flask with a rod-shaped magnet and keep stirring at medium speed. Weigh 300 mg of analytically pure Pluronic F127 molecules and add them to the above conical flask, stir to fully dissolve. Add 400 μg of 3, 3', 5, 5'-tetramethylbenzidine (TMB) powder to it, fully sonicate, and maintain medium-speed stirring at room temperature for 6 hours. Weigh 12 mg of dopamine (DA) monomer powder and dissolve it in 8 mL of Tris buffer (pH 8), then add the mixed solution to the above reaction system and stir at room temperature for 16 hours. Centrifuge, retain the precipitate below, wash the precipitate alternately with ethanol and acetone 3 times, wash it with water 2 times, collect the centrifugal precipitate sample into a centrifuge tube, prepare it into a concentration of 0.1-5 mg / mL solution, and store it in a refrigerator at 4℃.

[0056] 2. Chemotherapy drug loading The PDA solution was centrifuged and the preservation solution was discarded. 1 mL of Tris (pH 8) buffer was added, and then mixed with Tris (pH 8) solution of hydroxy-paclitaxel (PTX-OH), and stirred at medium speed for 10 minutes at room temperature. Subsequently, a Tris solution of doxorubicin (DOX) equal to that of PTX was added, and the mass volume ratio of mesoporous polydopamine nanospheres, chemotherapy drugs and buffer solution was 2.0 mg: 1 mg: 5 mL; the reaction was carried out at room temperature in the dark for 20 hours, centrifuged, and the solid particles were washed alternately with methanol and water twice to obtain polydopamine nanospheres (PDA@PD) loaded with dual drugs (PTX and DOX). The prepared PDA@PD was stored in a 5% ethanol aqueous solution and stored in a refrigerator at 4°C.

[0057] 3. Construction of a spherical nucleic acid structure with PDA as the core (outer dense nucleic acid layer) PDA@PD and 2 times the equivalent of aptamer nucleic acid single-stranded T20-DNA were added to a Tris buffer solution with a pH of 8. Under N2 protection, the mixture was stirred at room temperature for 24 hours and washed with water 5 times. The precipitate was collected to obtain the dual-drug loaded spherical nucleic acid (PDA-SNA).

[0058] Example 3 A method for loading chemotherapeutic drugs in a targeted drug delivery system based on a multivalent conjugate of polydopamine nanospheres coupled to aptamers, comprising the following steps: 1. Preparation of hollow mesoporous polydopamine nanospheres The reaction mechanism of dopamine oxidative self-polymerization is as follows: ; In the formula, n is a natural number greater than 2.

[0059] At room temperature, add 40 mL of deionized water and 25 mL of anhydrous ethanol to a conical flask with a rod-shaped magnet and keep stirring at medium speed. Weigh 200 mg of analytically pure Pluronic F127 molecules and add them to the above conical flask, stir to fully dissolve. Add 500 μg of 3, 3', 5, 5'-tetramethylbenzidine (TMB) powder to it, fully ultrasonicate, and maintain medium-speed stirring at room temperature for 6 hours. Weigh 8 mg of dopamine (DA) monomer powder and dissolve it in 6 mL of Tris buffer (pH 8), then add the mixed solution to the above reaction system and stir at room temperature for 28 hours. Centrifuge, retain the precipitate below, wash the precipitate alternately with ethanol and acetone 5 times, wash it with water 2 times, collect the centrifugal precipitate sample into a centrifuge tube, prepare it into a concentration of 0.1-5 mg / mL solution, and store it in a refrigerator at 4℃.

[0060] 2. Chemotherapy drug loading The PDA solution was centrifuged and the preservation solution was discarded. 1 mL of Tris (pH 8) buffer was added, and then mixed with Tris (pH 9) solution of hydroxy-paclitaxel (PTX-OH), and stirred at medium speed for 10 minutes at room temperature. Subsequently, a Tris solution of doxorubicin (DOX) equal to that of PTX was added, and the mass volume ratio of mesoporous polydopamine nanospheres, chemotherapy drugs and buffer solution was 1.8 mg: 1 mg: 4 mL; the reaction was carried out at room temperature in the dark for 28 hours, centrifuged, and the solid particles were washed alternately with methanol and water for 4 times to obtain polydopamine nanospheres (PDA@PD) loaded with dual drugs (PTX and DOX). The prepared PDA@PD was stored in a 5% ethanol aqueous solution and stored in a refrigerator at 4°C.

[0061] 3. Construction of a spherical nucleic acid structure with PDA as the core (outer dense nucleic acid layer) PDA@PD and 2 times the equivalent of aptamer nucleic acid single-stranded T20-DNA were added to a Tris buffer solution with a pH of 8.5. Under Ar gas protection, the mixture was stirred at room temperature for 24 hours, washed with water 4 times, and the precipitate was collected to obtain the dual-drug loaded spherical nucleic acid (PDA-SNA). The characterization diagram is shown in the figure. Figure 7 As shown in a.

[0062] The TEM characterization images of the products prepared in this example, PDA (mesoporous polydopamine nanospheres), PDA@PD (mesoporous polydopamine nanospheres loaded with drugs) and PDA-SNA (mesoporous polydopamine nanospheres loaded with drugs with high-density nucleic acid modified on the surface) are shown in FIG. Figure 6 As shown, from the SEM image, it can be observed that PDA is spherical, with a relatively uniform particle size, and there is no obvious change in the morphology after drug loading and modification; and through TEM, it can be found that its structure is a hollow mesoporous structure, and the hollow mesoporous structure obviously disappears in part after drug loading and modification.

[0063] Comparative Example 1 This comparative example is to replace the aptamer nucleic acid single-strand T20-DNA in Example 3 with NH2-PEG to obtain drug-loaded PDA-PEG. Figure 7 As shown in b.

[0064] Comparative Example 2 This comparative example is a drug-loaded PDA-RSNA prepared by replacing the single-stranded aptamer nucleic acid T20-DNA in Example 3 with an R-DNA nucleotide chain (sequence shown in SEQ ID No. 13). Figure 7 As shown in c.

[0065] Application Example 1 Taking the PDA-SNA prepared in Example 3 as an example, the following detection experiments were carried out: 1. Cellular uptake experiment: Rho-PDA is obtained by modifying PDA with rhodamine dye (Rho): 1 mg of rhodamine B and 1 mg of hollow mesoporous PDA were stirred in water at room temperature for 12 hours, then centrifuged, the supernatant was discarded, washed with water 5 times, and then prepared into a 1 mg / mL aqueous solution and stored at 4°C for use. Cy3-PDA-SNA was prepared by referring to the steps of Example 3, wherein the T20-DNA chain shown in the sequence SEQ ID No. 11 was selected in step 3.

[0066] The uptake efficiency experiment of mouse and human triple-negative breast cancer cells (4T1, MCF-7) and human normal liver cells (HL-7702) was as follows: 4T1, MCF-7 and HL-7702 were incubated with culture medium containing Rho-PDA (PDA 40 μg) and Cy3-PDA-SNA (PDA 40 μg) at constant temperature for 1-6 hours, and then the nuclei were stained with Hoechest dye for 10 minutes, washed with PBS three times, and the cell uptake of the sample was observed with a laser confocal microscope. The results are shown in Figure 2. Figure 8-10 shown.

[0067] Depend on Figure 8 and Fig. 9 It can be seen that: compared with the PDA material with an unmodified outer layer, the PDA-SNA material with a dense aptamer nucleic acid modified outer layer can be more efficiently taken up by both TNBC cells, but not by normal cells (HL7702 cells) ( Fig.10 ). This proves that PDA-SNA can efficiently and specifically identify tumor cells.

[0068] 2. Flow cytometry experiment of cellular uptake efficiency 500,000 MCF-7 cells or 4T1 cells were seeded into the wells of a cell culture dish. The final volume for each well was 1.5 mL. The cells were incubated for 16 h to allow them to attach to the dish wall. The cells were incubated with Cy3-labeled DNA (Cy3-T20-DNA), Cy3-PDA-SNA, and rhodamine-labeled PDA (Rho-PDA), all at a PDA concentration of 20 μg mL -1 ; Incubate in an incubator for 6 h. Then, cells were digested with Typsin-EDTA, washed 3 times with PBS, and resuspended in PBS (1 mL). Cells were analyzed by flow cytometry equipped with a 488 nm laser. Red fluorescence emitted by the material was detected on the flow cytometer. In all cases, 10,000 cells were counted. Fig.11 It is known that the cellular uptake efficiency of several samples was calculated after repeated experiments as shown in Figure 1. The results of the flow cytometry experiment show that compared with chain-shaped nucleic acids or conventional nanomaterials PDA, the three-dimensional structured PDA-SNA prepared by combining the two has a better cellular internalization efficiency (2-3 orders of magnitude higher than the former two).

[0069] 3. In vitro antitumor activity assay (MTT assay) MCF-7 cells were seeded in 96-well plates, and double-naked drugs, drug-loaded PDA, drug-loaded PDA-PEG, and drug-loaded PDA-SNA (containing DOX at concentrations of 1.5, 3.5, 5.5, 7.5, 9.5, and 11.5 μg mL −1 , containing PTX concentration twice that of DOX), incubated for 4 h, of which the laser irradiation group was irradiated with 808 nm laser for 10 min, then the cells were washed and 50 μg of MTT was added to the wells and incubated for 24 h, and then 150 μL of dimethyl sulfoxide was added to react at 37 ° C for 10 min, and the absorbance at 490 nm was detected by an enzyme marker to calculate the cell survival rate. The results are shown in Fig.12 As shown in the left picture.

[0070] 4T1 cells were seeded in 96-well plates, and double naked drugs (P+D), PDA, PDA-PEG, and PDA-SNA (containing DOX at concentrations of 1, 1.5, 2.5, 3.5, 4.5, and 5 μg mL −1 , containing PTX concentration twice that of DOX), incubated for 4 hours, of which the laser irradiation group was irradiated with 808nm laser for 10 minutes, then the cells were washed and 50μg MTT was added to the wells for incubation for 24 hours, and then 150μL dimethyl sulfoxide was added to react at 37℃ for 10 minutes, and the absorbance at 490nm was detected by an enzyme marker to calculate the cell survival rate. The results are shown in Fig.12 As shown in the picture on the right.

[0071] In vitro antitumor test results (see Fig.12 ) showed that the drug-loaded PDA-SNA in the present invention has a greater cell killing effect under the same illumination conditions, and has a better therapeutic effect than the material whose outer layer is modified with an equal molecular weight polyethylene glycol (PEG) chain.

[0072] 3. Cell apoptosis experiment In cell culture plates, 2 × 10 5 4T1 / MCF-7 cells were inoculated at a density of 100 cells / well and incubated with dual-drug bare cells, PDA@PD, dual-drug loaded PDA-PEG, dual-drug loaded PDA-RSNA and dual-drug loaded PDA-SNA for 2-4 h. -2 ) for 10 min, wash and digest the cells, centrifuge at 4°C for 5 min, resuspend the cells, add 5 μL Annexin V-FITC and 5 μL PI staining solution to each tube in the dark, incubate at room temperature for 15 min, filter the cells (300 mesh) and detect the level of cell apoptosis using flow cytometry.

[0073] Cell apoptosis assay (see Fig.13 ) further proved that compared with other groups, the PDA-SNA designed in the present invention can induce cell apoptosis more efficiently in the SNA group, greatly improving the therapeutic index.

[0074] The room temperature described in the above embodiment is 10-40°C, which is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A multivalent conjugate targeted delivery system based on polydopamine nanospheres coupled to aptamers, characterized in that: The targeted delivery system includes mesoporous polydopamine nanospheres and targeted nucleic acid aptamers modified on their surfaces; The nucleotide sequence of the targeted nucleic acid aptamer is selected from any one of the nucleotide sequences shown in SEQ ID No. 1 to SEQ ID No. 6, and the 5' end thereof is modified with an NH2-C6- group.

2. The multivalent conjugate targeted delivery system based on polydopamine nanospheres coupled to aptamers according to claim 1, characterized in that: The nucleotide sequence of the targeted nucleic acid aptamer is shown in SEQ ID No. 5, and the 5' end thereof is modified with an NH2-C6- group.

3. The multivalent conjugate targeted delivery system based on polydopamine nanospheres coupled to aptamers according to claim 2, characterized in that: The hollow mesoporous structure on the mesoporous polydopamine nanospheres is used to load chemotherapeutic drugs, and the loading amount of chemotherapeutic drugs in the mesoporous polydopamine nanospheres is 30-40%wt.

4. The method for loading chemotherapeutic drugs with the multivalent conjugate targeted delivery system according to any one of claims 1 to 3, characterized in that: Here are the steps: (1) TMB is added dropwise to the alcohol-water solution of F127 molecules, and after mixing, dopamine-containing Tris buffer is added under stirring. The reaction is stirred at room temperature until complete, and the resulting precipitate is the mesoporous polydopamine nanospheres; (2) mixing the mesoporous polydopamine nanospheres prepared in step (1) and the chemotherapeutic drug in a Tris buffer, and after the reaction is completed at room temperature in the dark, centrifuging and washing to obtain the drug-loaded polydopamine nanospheres; (3) The drug-loaded polydopamine nanospheres and targeted nucleic acid aptamers of step (2) are stirred and reacted in a Tris buffer in an inert atmosphere. After the reaction is completed, the mixture is centrifuged and washed to remove impurities, thereby obtaining a drug-loaded multivalent conjugate targeted delivery system.

5. The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system according to claim 4, characterized in that: In the step (1), the mass ratio of F127 molecules, TMB and dopamine is 80-300:0.2-0.5:2-12; the volume ratio of ethanol to water in the alcohol aqueous solution is 3-6:4-10; and the concentration of F127 molecules in the alcohol aqueous solution is 1-9 mg / mL.

6. The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system according to claim 4, characterized in that: In the step (2), the mass ratio of the mesoporous polydopamine nanospheres to the chemotherapeutic drugs is 1.5-2:1; the types of the chemotherapeutic drugs are one or more; and the reaction time at room temperature and in the dark is 20-28 hours.

7. The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system according to claim 5, characterized in that: The chemotherapy drugs are hydroxy-paclitaxel and doxorubicin, and the mass ratio of hydroxy-paclitaxel to doxorubicin is 1:

1.

8. The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system according to claim 5, characterized in that: In the step (3), the equivalent ratio of the drug-loaded polydopamine nanospheres to the targeted nucleic acid aptamer is 1:2; the reaction is stirred at room temperature for 20-28 hours.

9. The method for loading chemotherapeutic drugs with a multivalent conjugate targeted delivery system according to any one of claims 5 to 8, characterized in that: The pH of the Tris buffer is 8-9.

10. A cancer drug prepared by the method of claim 9.

Citation Information

Cited By

  • Preparation method and application of melanin-like polydopamine nanoparticles

    CN116239770A

  • Preparation method and application of melanin-like polydopamine nanoparticles

    CN116239770B

  • Preparation method of thermosensitive hydrogel system loaded with Annexin V modified mesoporous polydopamine drug-loaded nanoparticles

    CN119745836A

  • Amidoxime and polydopamine modified loofah sponge adsorbing material and preparation method thereof

    CN119869465A